MicroRNA-542-3p inhibits tumour angiogenesis by targeting Angiopoietin-2

Journal of Pathology

Volumn 232, Issue 5, 2014, Pages 499-508

  He, Ting ^a   Qi, Feifei ^a   Jia, Lin ^a   Wang, Shan ^a   Song, Nan ^a   Guo, Lifang ^a   Fu, Yan ^a   Luo, Yongzhang ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

angiogenesis; Angiopoietin 2; breast cancer; miR 542 3p

Indexed keywords

ANGIOPOIETIN 2; MICRORNA; MICRORNA 542 3P; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

3' UNTRANSLATED REGION; ALGORITHM; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BINDING SITE; BREAST CARCINOMA; CANCER INHIBITION; CANCER STAGING; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WILD TYPE;

ANGIOGENESIS; ANGIOPOIETIN-2; BREAST CANCER; MIR-542-3P;

3' UNTRANSLATED REGIONS; ANGIOPOIETIN-2; ANIMALS; BINDING SITES; BREAST NEOPLASMS; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FEMALE; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICRORNAS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 84895923770     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4324     Document Type: Article

References (43)

1. Folkman J., Is angiogenesis an organizing principle in biology and medicine? J Pediatr Surg 2007; 42: 1-11.
2. Weis SM, Cheresh DA,. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011; 17: 1359-1370.
3. Bergers G, Benjamin LE,. Angiogenesis: tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-410.
4. Maisonpierre PC,. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60.
5. Huang H, Bhat A, Woodnutt G, et al. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010; 10: 575-585.
6. Augustin HG, Young Koh G, Thurston G, et al. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10: 165-177.
7. Saharinen P, Bry M, Alitalo K,. How do angiopoietins Tie with vascular endothelial growth factors? Curr Opin Hematol 2010; 17: 198-205.
8. Huang Y, Song N, Ding Y, et al. Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res 2009; 69: 7529-7537.
9. Gale N, Thurston G, Hackett S, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin. Dev Cell 2002; 3: 411-423.
10. De Palma M, Naldini L,. Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. Clin Cancer Res 2011; 17: 5226-5232.
11. Mazzieri R, Pucci F, Moi D, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011; 19: 512-526.
12. Koh YJ, Kim HZ, Hwang SI, et al. Double antiangiogenic protein, DAAP, pargeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 2010; 18: 171-184.
13. Holopainen T, Saharinen P, D'Amico G, et al. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst 2012; 104: 461-475.
14. Filipowicz W, Bhattacharyya SN, Sonenberg N,. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 2008: 102-114.
15. Fish J, Srivastava D,. MicroRNAs: opening a new vein in angiogenesis research. Sci Signal 2009; 2: pe1.
16. Lewis B, Burge C, Bartel D,. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
17. Friedman R, Farh K, Burge C, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
18. Shi H, Huang Y, Zhou H, et al. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 2007; 110: 2899-2906.
19. Huang Y, Shi H, Zhou H, et al. The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood 2006; 107: 3564-3571.
20. Song N, Huang Y, Shi H, et al. Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1/CXCR4 axis. Cancer Res 2009; 69: 6057-6064.
21. He Y, Chang G, Zhan S, et al. Soluble tissue factor has unique angiogenic activities that selectively promote migration and differentiation but not proliferation of endothelial cells. Biochem Biophys Res Commun 2008; 370: 489-494.
22. Ding Y, Huang Y, Song N, et al. NFAT1 mediates placental growth factor-induced myelomonocytic cell recruitment via the induction of TNFα. J Immunol 2010; 184: 2593-2601.
23. Korff T, Augustin HG,. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol 1998; 143: 1341-1352.
24. Li H, Wang L, Ye L, et al. Influence of Pseudomonas aeruginosa quorum sensing signal molecule N-(3-oxododecanoyl) homoserine lactone on mast cells. Med Microbiol Immunol 2009; 198: 113-121.
25. Krek A, Grün D, Poy M, et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495-500.
26. Betel D, Wilson M, Gabow A, et al. The http://microRNA.org resource: targets and expression. Nucleic Acids Res 2008; 36: D149-153.
27. Cai M, Zhang H, Hui R,. Single chain Fv antibody against angiopoietin-2 inhibits VEGF-induced endothelial cell proliferation and migration in vitro. Biochem Biophys Res Commun 2003; 309: 946-951.
28. Yoon S, Choi YC, Lee S, et al. Induction of growth arrest by miR-542-3p that targets survivin. FEBS Lett 2010; 584: 4048-4052.
29. Schrauder MG, Strick R, Schulz-Wendtland R, et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One 2012; 7: e29770.
30. Fagiani E, Lorentz P, Kopfstein L, et al. Angiopoietin-1 and -2 exert antagonistic functions in tumor angiogenesis, yet both induce lymphangiogenesis. Cancer Res 2011; 71: 5717-5727.
31. Murdoch C, Tazzyman S, Webster S, et al. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol 2007; 178: 7405-7411.
32. Minami T, Jiang S, Schadler K, et al. The calcineurin-NFAT-angiopoietin-2 signaling axis in lung endothelium is critical for the establishment of lung metastases. Cell Rep 2013; 4: 709-723.
33. Scholz A, Rehm VA, Rieke S, et al. Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. Am J Gastroenterol 2007; 102: 2471-2481.
34. Diaz-Sanchez A, Matilla A, Nunez O, et al. Serum angiopoietin-2 level as a predictor of tumor invasiveness in patients with hepatocellular carcinoma. Scand J Gastroenterol 2013; 48: 334-343.
35. Park JH, Park KJ, Kim YS, et al. Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 2007; 132: 200-206.
36. Naumnik W, Naumnik B, Niewiarowska K, et al. Angiogenic axis angiopoietin-1 and angiopoietin-2/Tie-2 in non-small cell lung cancer: a bronchoalveolar lavage and serum study. Adv Exp Med Biol 2013; 788: 341-348.
37. Gu J, Yamamoto H, Ogawa M, et al. Hypoxia-induced up-regulation of angiopoietin-2 in colorectal cancer. Oncol Rep 2006; 15: 779-783.
38. Helfrich I, Edler L, Sucker A, et al. Angiopoietin-2 levels are associated with disease progression in metastatic mMalignant melanoma. Clin Cancer Res 2009; 15: 1384-1392.
39. Caine GJ, Blann AD, Stonelake PS, et al. Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest 2003; 33: 883-890.
40. Rykala J, Przybylowska K, Majsterek I, et al. Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables. Pathol Oncol Res 2011; 17: 809-817.
41. Carmeliet P, Jain RK,. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10: 417-427.
42. D'Amato RJ, Adamis AP,. Angiogenesis inhibition in age-related macular degeneration. Ophthalmology 1995; 102: 1261-1262.
43. Folkman J., Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.